Fredun Pharmaceuticals Ltd is Rated Buy

Current Rating and Its Significance

MarketsMOJO’s 'Buy' rating for Fredun Pharmaceuticals Ltd indicates a positive outlook on the stock, suggesting it is expected to outperform the broader market over the medium to long term. This recommendation is based on a comprehensive evaluation of the company’s quality, valuation, financial trend, and technical indicators. Investors should view this rating as a signal that the stock presents an attractive opportunity relative to its peers, supported by solid fundamentals and favourable market dynamics.

Quality Assessment

As of 14 February 2026, Fredun Pharmaceuticals holds an average quality grade. This reflects a stable operational foundation with consistent growth in key financial metrics. The company has demonstrated healthy long-term growth, with net sales increasing at an annual rate of 38.09% and operating profit expanding at an even more impressive 58.31%. Such growth rates underscore the company’s ability to scale its operations effectively within the Pharmaceuticals & Biotechnology sector, despite being a microcap entity.

Valuation Perspective

The valuation grade for Fredun Pharmaceuticals is currently attractive. The stock trades at a discount compared to its peers’ historical valuations, supported by a return on capital employed (ROCE) of 20.2%, which is a robust indicator of efficient capital utilisation. Additionally, the enterprise value to capital employed ratio stands at a modest 3.6, signalling that the market is valuing the company conservatively relative to its capital base. The company’s PEG ratio of 0.5 further suggests that earnings growth is not fully priced in, offering potential upside for investors.

Financial Trend and Performance

The financial trend for Fredun Pharmaceuticals is very positive. The latest data shows the company has declared positive results for seven consecutive quarters, highlighting consistent operational momentum. Quarterly net sales have surged to ₹160.93 crores, reflecting a 56.70% growth rate, while profit before tax excluding other income (PBT less OI) reached a peak of ₹14.00 crores. Operating profit before depreciation and interest (PBDIT) also hit a record ₹26.34 crores. Over the past year, the stock has delivered an impressive 148.05% return, with profits rising by 81.2%, underscoring strong earnings growth alongside market appreciation.

Technical Indicators

Technically, Fredun Pharmaceuticals is rated bullish. The stock has exhibited strong momentum, with a 6.52% gain over the past three months and a remarkable 73.84% increase over six months. Year-to-date returns stand at 14.93%, and the stock has outperformed the BSE500 index over one year, three months, and three years. Institutional investors have increased their stake by 2.33% in the previous quarter, now holding 3.94% collectively, signalling growing confidence from market professionals who typically conduct rigorous fundamental analysis.

Market Position and Outlook

Fredun Pharmaceuticals operates within the Pharmaceuticals & Biotechnology sector, a space characterised by innovation and steady demand. Despite its microcap status, the company’s strong growth trajectory and improving profitability metrics position it favourably against peers. The combination of attractive valuation, solid financial performance, and positive technical signals suggests that the stock is well placed to continue delivering value to shareholders.

Investor Considerations

Investors should note that the 'Buy' rating reflects a balanced view of Fredun Pharmaceuticals’ current strengths and market potential. The company’s average quality grade suggests room for operational improvement, but this is offset by very positive financial trends and attractive valuation metrics. The bullish technical stance further supports the case for accumulation, particularly for investors seeking exposure to a microcap pharmaceutical stock with strong growth prospects.

Summary of Key Metrics as of 14 February 2026

To summarise, the stock’s performance indicators as of today include:

• One-day change: -0.66%
• One-week gain: +10.07%
• One-month gain: +21.23%
• Three-month gain: +6.52%
• Six-month gain: +73.84%
• Year-to-date gain: +14.93%
• One-year gain: +148.05%

These figures highlight the stock’s strong momentum and market-beating returns over multiple time horizons, reinforcing the rationale behind the current 'Buy' rating.

Conclusion

Fredun Pharmaceuticals Ltd’s 'Buy' rating by MarketsMOJO, last updated on 29 July 2025, remains well justified by the company’s current fundamentals and market performance as of 14 February 2026. Investors looking for growth opportunities in the Pharmaceuticals & Biotechnology sector may find this stock an appealing addition to their portfolio, given its attractive valuation, positive financial trends, and bullish technical outlook.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →